GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) yesterday touted results from a Phase III study investigating the triple-combination therapy fluticasone furoate/umeclidnium/vilanterol for patients with chronic obstructive pulmonary disease. The 1,810-patient Fulfil study is a randomized, double-blinded trial comparing once-daily FF/UMEC/VI against AstraZeneca‘s (NYSE:AZN) Symbicort Turbohaler dry powder inhaler, a twice-daily combination of budesonide and formoterol. Patients in the FF/UMEC/VI […]
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use […]
Adherium Limited said last week it closed an oversubscribed Australian initial public offering, raising $25.8 million (AU$35 million) with $2.2 million (AU$3 million) coming from pharmaceutical giant AstraZeneca. Adherium is a digital health company that is developing technology targeting suboptimal medication use and remote patient management for chronic disease sufferers, the New Zealand-based company said. […]
Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
MASSDEVICE ON CALL — Doctors are split when it comes to health care reform, according to a new survey from the Deloitte Center for Health Solutions.
Of the 501 doctors surveyed, 44 percent said the law was "a good start," while another 44 percent said health care reform was "a step in the wrong direction."
Overall, the doctors worried that the new system would increase access to government insurance programs without reducing costs, leaving fewer people uninsured but increasing emergency room wait times and lowering the total quality of care.
Stryker Corp. (NYSE:SYK) agreed to pay $150 million in up-front cash for Memometal Technologies SA, plus another $12 million in milestone payments.
Bruz, France-based Memometal makes implants for the extremities using shape memory alloys. The $162 million value of the deal is a 5.4x multiple of the $30 million the company posted to its top line last year.
MASSDEVICE ON CALL — Johnson & Johnson’s (NYSE:JNJ) may be looking at its proposed mega-merger with Synthes as a way to save its orthopedics business.
Under the terms of the merger agreement between the two companies, Forest Labs will pay $30 per share in cash, with additional milestone payments of up to $6 per share based on the commercial success of Clinical Data’s new antidepressant drug, Viibryd, according to the companies.